159 related articles for article (PubMed ID: 35397664)
1. Population pharmacokinetics of rucaparib in patients with advanced ovarian cancer or other solid tumors.
Green ML; Ma SC; Goble S; Giordano H; Maloney L; Simmons AD; Beltman J; Harding TC; Xiao JJ
Cancer Chemother Pharmacol; 2022 May; 89(5):671-682. PubMed ID: 35397664
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors.
Shapiro GI; Kristeleit RS; Burris HA; LoRusso P; Patel MR; Drew Y; Giordano H; Maloney L; Watkins S; Goble S; Jaw-Tsai S; Xiao JJ
Clin Pharmacol Drug Dev; 2019 Jan; 8(1):107-118. PubMed ID: 29799676
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment.
Grechko N; Skarbova V; Tomaszewska-Kiecana M; Ramlau R; Centkowski P; Drew Y; Dziadziuszko R; Zemanova M; Beltman J; Nash E; Habeck J; Liao M; Xiao J
Cancer Chemother Pharmacol; 2021 Aug; 88(2):259-270. PubMed ID: 33909097
[TBL] [Abstract][Full Text] [Related]
4. Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib.
Liao M; Beltman J; Giordano H; Harding TC; Maloney L; Simmons AD; Xiao JJ
Clin Pharmacokinet; 2022 Nov; 61(11):1477-1493. PubMed ID: 36107395
[TBL] [Abstract][Full Text] [Related]
5. Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma.
O'Malley DM; Oza AM; Lorusso D; Aghajanian C; Oaknin A; Dean A; Colombo N; Weberpals JI; Clamp AR; Scambia G; Leary A; Holloway RW; Gancedo MA; Fong PC; Goh JC; Swisher EM; Maloney L; Goble S; Lin KK; Kwan T; Ledermann JA; Coleman RL
Gynecol Oncol; 2022 Dec; 167(3):404-413. PubMed ID: 36273926
[TBL] [Abstract][Full Text] [Related]
6. ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer.
Monk BJ; Coleman RL; Fujiwara K; Wilson MK; Oza AM; Oaknin A; O'Malley DM; Lorusso D; Westin SN; Safra T; Herzog TJ; Marmé F; N Eskander R; Lin KK; Shih D; Goble S; Grechko N; Hume S; Maloney L; McNeish IA; Kristeleit RS
Int J Gynecol Cancer; 2021 Dec; 31(12):1589-1594. PubMed ID: 34593565
[TBL] [Abstract][Full Text] [Related]
7. Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib.
Kwan TT; Oza AM; Tinker AV; Ray-Coquard I; Oaknin A; Aghajanian C; Lorusso D; Colombo N; Dean A; Weberpals J; Severson E; Vo LT; Goble S; Maloney L; Harding T; Kaufmann SH; Ledermann JA; Coleman RL; McNeish IA; Lin KK; Swisher EM
JAMA Oncol; 2021 Dec; 7(12):1772-1781. PubMed ID: 34647981
[TBL] [Abstract][Full Text] [Related]
8. Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease.
Dal Molin GZ; Westin SN; Coleman RL
Future Oncol; 2018 Dec; 14(30):3101-3110. PubMed ID: 30105925
[TBL] [Abstract][Full Text] [Related]
9. Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2.
Konecny GE; Oza AM; Tinker AV; Oaknin A; Shapira-Frommer R; Ray-Coquard I; Aghajanian C; Coleman RL; O'Malley DM; Leary A; Chen LM; Provencher D; Ma L; Brenton JD; Castro C; Green M; Simmons AD; Beltman J; Harding T; Lin KK; Goble S; Maloney L; Kristeleit RS; McNeish IA; Swisher EM; Xiao JJ
Gynecol Oncol; 2021 Jun; 161(3):668-675. PubMed ID: 33752918
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed,
Kristeleit RS; Oaknin A; Ray-Coquard I; Leary A; Balmaña J; Drew Y; Oza AM; Shapira-Frommer R; Domchek SM; Cameron T; Maloney L; Goble S; Lorusso D; Ledermann JA; McNeish IA
Int J Gynecol Cancer; 2019 Nov; 29(9):1396-1404. PubMed ID: 31685558
[TBL] [Abstract][Full Text] [Related]
11. PARP activity in peripheral blood lymphocytes as a predictive biomarker for PARP inhibition in tumor tissues - A population pharmacokinetic/pharmacodynamic analysis of rucaparib.
Wang DD; Li C; Sun W; Zhang S; Shalinsky DR; Kern KA; Curtin NJ; Sam WJ; Kirkpatrick TR; Plummer R
Clin Pharmacol Drug Dev; 2015 Mar; 4(2):89-98. PubMed ID: 27128213
[TBL] [Abstract][Full Text] [Related]
12. Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3.
Clamp AR; Lorusso D; Oza AM; Aghajanian C; Oaknin A; Dean A; Colombo N; Weberpals JI; Scambia G; Leary A; Holloway RW; Amenedo Gancedo M; Fong PC; Goh JC; O'Malley DM; Armstrong DK; Banerjee S; García-Donas J; Swisher EM; Cameron T; Goble S; Coleman RL; Ledermann JA
Int J Gynecol Cancer; 2021 Jul; 31(7):949-958. PubMed ID: 34103386
[TBL] [Abstract][Full Text] [Related]
13. A Population Pharmacokinetic Meta-Analysis of Veliparib, a PARP Inhibitor, Across Phase 1/2/3 Trials in Cancer Patients.
Stodtmann S; Nuthalapati S; Eckert D; Kasichayanula S; Joshi R; Bach BA; Mensing S; Menon R; Xiong H
J Clin Pharmacol; 2021 Sep; 61(9):1195-1205. PubMed ID: 33894017
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of absorption, distribution, metabolism, and excretion of [
Liao M; Watkins S; Nash E; Isaacson J; Etter J; Beltman J; Fan R; Shen L; Mutlib A; Kemeny V; Pápai Z; van Tilburg P; Xiao JJ
Invest New Drugs; 2020 Jun; 38(3):765-775. PubMed ID: 31250355
[TBL] [Abstract][Full Text] [Related]
15. A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline
Kristeleit R; Shapiro GI; Burris HA; Oza AM; LoRusso P; Patel MR; Domchek SM; Balmaña J; Drew Y; Chen LM; Safra T; Montes A; Giordano H; Maloney L; Goble S; Isaacson J; Xiao J; Borrow J; Rolfe L; Shapira-Frommer R
Clin Cancer Res; 2017 Aug; 23(15):4095-4106. PubMed ID: 28264872
[No Abstract] [Full Text] [Related]
16. The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma.
Colombo N; Oza AM; Lorusso D; Aghajanian C; Oaknin A; Dean A; Weberpals JI; Clamp AR; Scambia G; Leary A; Holloway RW; Gancedo MA; Fong PC; Goh JC; O'Malley DM; Armstrong DK; Banerjee S; García-Donas J; Swisher EM; Meunier J; Cameron T; Maloney L; Goble S; Bedel J; Ledermann JA; Coleman RL
Gynecol Oncol; 2020 Oct; 159(1):101-111. PubMed ID: 32861537
[TBL] [Abstract][Full Text] [Related]
17. Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2).
Swisher EM; Kwan TT; Oza AM; Tinker AV; Ray-Coquard I; Oaknin A; Coleman RL; Aghajanian C; Konecny GE; O'Malley DM; Leary A; Provencher D; Welch S; Chen LM; Wahner Hendrickson AE; Ma L; Ghatage P; Kristeleit RS; Dorigo O; Musafer A; Kaufmann SH; Elvin JA; Lin DI; Chambers SK; Dominy E; Vo LT; Goble S; Maloney L; Giordano H; Harding T; Dobrovic A; Scott CL; Lin KK; McNeish IA
Nat Commun; 2021 May; 12(1):2487. PubMed ID: 33941784
[TBL] [Abstract][Full Text] [Related]
18. Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety.
Oaknin A; Oza AM; Lorusso D; Aghajanian C; Dean A; Colombo N; Weberpals JI; Clamp AR; Scambia G; Leary A; Holloway RW; Amenedo Gancedo M; Fong PC; Goh JC; O'Malley DM; Armstrong DK; Banerjee S; García-Donas J; Swisher EM; Cameron T; Maloney L; Goble S; Ledermann JA; Coleman RL
Cancer Med; 2021 Oct; 10(20):7162-7173. PubMed ID: 34549539
[TBL] [Abstract][Full Text] [Related]
19. Real-World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10.
Drew Y; Kristeleit RS; Oaknin A; Ray-Coquard I; Haris NM; Swisher EM
Oncologist; 2020 Jan; 25(1):e109-e119. PubMed ID: 31575788
[TBL] [Abstract][Full Text] [Related]
20. Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma.
Oza AM; Lorusso D; Aghajanian C; Oaknin A; Dean A; Colombo N; Weberpals JI; Clamp AR; Scambia G; Leary A; Holloway RW; Gancedo MA; Fong PC; Goh JC; O'Malley DM; Armstrong DK; Banerjee S; García-Donas J; Swisher EM; Cella D; Meunier J; Goble S; Cameron T; Maloney L; Mörk AC; Bedel J; Ledermann JA; Coleman RL
J Clin Oncol; 2020 Oct; 38(30):3494-3505. PubMed ID: 32840418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
